A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Duvelisib (Primary) ; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Infinity Pharmaceuticals; Verastem
- 20 Jun 2014 Planned End Date changed from 1 Dec 2019 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
- 20 Jun 2014 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2018 as reported by ClinicalTrials.gov record.
- 31 May 2014 Planned number of patients changed from 150 to 307 as reported by European Clinical Trials Database record.